U.S. Markets closed

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.05+0.02 (+0.40%)
At close: 4:00PM EDT
People also watch
CTICARRYCRISCLDXEXEL

Agenus Inc.

3 Forbes Road
Lexington, MA 02421
United States
781-674-4400
http://www.agenusbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees255

Key Executives

NameTitlePayExercisedAge
Dr. Garo H. Armen Ph.D.Founder, Exec. Chairman & CEO1.06MN/A64
Ms. Christine M. KlaskinPrincipal Financial Officer, Principal Accounting Officer & VP of Fin.357.48kN/A51
Ms. Karen Higgins Valentine J.D.Chief Legal Officer, Chief Compliance Officer, Gen. Counsel & Sec.556.06kN/A45
Mr. Ozer BaysalChief Commercial Officer & Head of HR307.62kN/A61
Dr. Robert B. Stein Ph.D., M.D.Sr. R&D Advisor778.77kN/A66
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Agenus Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.